Newsletter | April 30, 2021

04.30.21 -- Overcoming The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies

 
The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies
 

The success of using viral vectors to deliver a molecular payload into a cell or replace defective genes with functional ones is an inflection point in the future of modern medicine. New technologies and additional capacity to address cell and gene therapy market growth and raw material shortages are necessary to support your product now and well into the future.

Practical And Innovative Solutions For AAV Development And Manufacturing
 

What are the current challenges and future promises of adeno-associated virus (AAV), lentivirus, and lipid nanoparticles in gene therapies? Explore case studies for neuromuscular degenerative indications, AAV technology and manufacturing, and strategies for navigating the regulatory environments in the U.S. and Europe.

Overcoming Commercialization Challenges For Cell And Gene Therapies
 

While cell and gene therapies offer great promises, treatments, and cures, challenges exist from development through the delivery of the drug products to patients. This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.

Solutions